Ashwagandha: Stress, Cognition, and What the Evidence Actually Shows

Ashwagandha has become one of the best-selling supplements in North America and Europe over the past five years. Search interest has roughly tripled since 2020. Influencers promote it for everything from anxiety relief to muscle growth to testosterone optimization. Some of those claims have substance. Others are ahead of the evidence. Withania somnifera — ashwagandha's botanical name — is a small evergreen shrub native to India, the Middle East, and parts of Africa. It has been used for over 3,000 years in Ayurvedic medicine as a rasayana, a rejuvenating tonic prescribed for stress, vitality, and longevity.

What has changed in the last decade is that ashwagandha has finally been subjected to randomised controlled trials. The picture that emerges is genuinely interesting — particularly for stress and cortisol modulation — though the cognitive evidence is more nuanced than supplement marketing suggests. Here is what the research actually shows.

What Is Ashwagandha?

Ashwagandha belongs to the Solanaceae (nightshade) family. The root and, to a lesser extent, the leaves contain the primary bioactive compounds: withanolides, a group of naturally occurring steroidal lactones. The most studied include withaferin A, withanolide D, and withanoside IV. Withanolides are believed to mediate most of ashwagandha's pharmacological effects, including its anti-stress, anti-inflammatory, and neuroprotective activity.

Ashwagandha is classified as an adaptogen — a substance that helps the body resist physiological and psychological stressors by modulating the hypothalamic-pituitary-adrenal (HPA) axis. This distinguishes it fundamentally from stimulant nootropics like modafinil or caffeine. Adaptogens don't push the system harder; they help it regulate more effectively. Ashwagandha does not produce acute alertness or euphoria. Its effects are modulatory, gradual, and most evident under conditions of stress.

The Stress and Cortisol Evidence

This is where ashwagandha's evidence base is strongest. A 2024 systematic review published in Explore analysed multiple RCTs and concluded that ashwagandha supplementation produced significant improvements across measures of stress, anxiety, and depression compared to placebo. The effect sizes for stress reduction were consistently moderate to large across the reviewed trials.

One of the most frequently cited individual studies is Chandrasekhar et al. (2012), a double-blind RCT involving 64 adults with a history of chronic stress. Participants received either 600mg/day of a full-spectrum ashwagandha root extract or placebo for 60 days. The ashwagandha group showed a 44% reduction in perceived stress (measured by the Perceived Stress Scale) and a 27.9% reduction in serum cortisol compared to baseline, with statistically significant differences from placebo on both measures.

A 2019 study by Lopresti et al. in Medicine found that 240mg/day of ashwagandha extract (Shoden, standardised to 35% withanolides) significantly reduced cortisol levels relative to placebo in stressed but otherwise healthy adults, along with improvements in sleep quality. The cortisol reduction was measurable by morning salivary cortisol, adding objective biomarker data to the subjective self-report measures.

The consistency across multiple trials is notable. While individual study sample sizes remain small (typically 40–100 participants), the direction of effect — reduced cortisol, reduced subjective stress — replicates across different extracts, doses, and populations. This is the area where confidence in ashwagandha is highest.

Cognitive Effects

The cognitive evidence is more recent and more mixed, but it is growing.

A 2022 double-blind RCT by Gopukumar et al. enrolled 50 adults with mild cognitive impairment and administered 600mg/day of ashwagandha root extract for 8 weeks. Compared to placebo, the ashwagandha group showed statistically significant improvements in immediate memory, general memory, executive function, sustained attention, and information processing speed as measured by the Cogstate battery. The effect sizes were moderate, and improvements were consistent across multiple cognitive domains rather than isolated to a single measure.

A 2024 study published in Nutrients extended this inquiry to healthy young adults — a population more relevant to typical nootropic users. Participants receiving ashwagandha showed significant improvements in word recall, reaction time, and picture recognition compared to placebo. This is noteworthy because demonstrating cognitive enhancement in healthy, young, non-impaired individuals is considerably harder than showing improvements in cognitively impaired populations.

The proposed cognitive mechanism is multifaceted: ashwagandha appears to reduce cortisol-mediated cognitive impairment (chronic stress damages the hippocampus), modulate GABAergic and cholinergic neurotransmission, and exhibit antioxidant and anti-inflammatory properties in neural tissue. Animal studies show withaferin A promotes neurite outgrowth and may support synaptic plasticity, though translating these findings to human cognition requires caution.

The Honest Limitations

• The cognitive RCTs have small sample sizes (50–60 participants)
• Most positive cognitive studies use specific branded extracts, which may not generalise to all products on the market
• It is difficult to separate ashwagandha's direct nootropic effects from indirect effects via stress reduction — if you reduce someone's cortisol, their cognition will improve as a consequence
• Long-term cognitive studies (beyond 8–12 weeks) are largely absent

Sleep Quality

Multiple trials report improvements in sleep quality with ashwagandha, particularly with the KSM-66 extract. A 2019 double-blind RCT published in Cureus found that 600mg/day of KSM-66 significantly improved sleep quality scores (Pittsburgh Sleep Quality Index), sleep onset latency, and overall restfulness in adults with insomnia. A 2020 meta-analysis confirmed the sleep benefit across multiple trials, with a moderate pooled effect size.

The mechanism likely involves GABA receptor modulation — triethylene glycol, a compound present in ashwagandha leaves, has been shown to promote sleep in animal models via GABAergic pathways. The cortisol-lowering effect also contributes: elevated evening cortisol is a well-established driver of sleep-onset insomnia.

Ashwagandha is not a sedative and should not be compared to melatonin or pharmaceutical sleep aids. It appears to improve sleep by reducing the physiological stress response that prevents sleep, rather than by directly inducing drowsiness.

Physical Performance

The physical performance data is one of the more surprising aspects of ashwagandha research. A 2015 study by Wankhede et al. examined resistance-trained men supplementing with 600mg/day of ashwagandha root extract over 8 weeks. The ashwagandha group increased their bench press 1RM by approximately 101 lbs compared to 57 lbs in the placebo group. The ashwagandha group also showed a significantly greater increase in arm muscle size and a 15% increase in testosterone relative to placebo.

A 2021 systematic review in the Journal of the International Society of Sports Nutrition pooled data from 12 studies and concluded that ashwagandha supplementation significantly improved VO2 max, upper and lower body strength, and recovery from exercise-induced muscle damage. The testosterone findings have been replicated across several small trials, though the magnitude of the effect is modest and unlikely to approach pharmacological intervention.

These results are plausible given ashwagandha's cortisol-lowering properties — chronic cortisol elevation is catabolic and inhibits muscle protein synthesis. By reducing cortisol, ashwagandha may create a hormonal environment more favourable to recovery and adaptation.

KSM-66 vs Sensoril: Which Extract?

Most of the rigorous clinical research on ashwagandha uses one of two branded, standardised extracts. Understanding the difference matters for product selection.

• KSM-66: A full-spectrum root extract standardised to at least 5% withanolides. Produced via a proprietary water-based extraction process without chemical solvents. KSM-66 is the most widely studied ashwagandha extract, with clinical data supporting its effects on stress, cognition, sleep, testosterone, and physical performance. The typical dose in trials is 300–600mg/day.
• Sensoril: Extracted from both root and leaf, standardised to at least 10% withanolides (higher concentration per mg than KSM-66). Sensoril tends to produce a more calming, relaxation-focused effect and is commonly used in studies targeting anxiety and cortisol. The typical dose in trials is 125–250mg/day, reflecting its higher withanolide content per milligram.

Neither is objectively superior. KSM-66 has a broader evidence base across more outcomes. Sensoril delivers more withanolides per milligram and may be preferred for users specifically targeting anxiety and cortisol reduction. Both are well-characterised and quality-controlled, which is more than can be said for many generic ashwagandha supplements on the market. If you are also considering rhodiola as an adaptogen, this ashwagandha vs rhodiola comparison breaks down how the two differ in mechanism and use case.

Dosing

• Standardised root extract (KSM-66 or equivalent): 300–600mg/day, typically divided into one or two doses. Most studies showing positive results use 600mg/day.
• Sensoril: 125–250mg/day, reflecting its higher withanolide concentration.
• Withanolide content: Look for products standardised to 0.3–1.5% withanolides for generic root extracts, or 5%+ for KSM-66, or 10%+ for Sensoril.
• Starting dose: Begin at 300mg/day for the first week, then increase to 600mg/day if well tolerated. Taking it with food may reduce the GI side effects some people experience.
• Timing: Morning or evening. For stress and cognitive effects, morning dosing is common. For sleep support, evening dosing 1–2 hours before bed is preferable. Some users split the dose (300mg morning, 300mg evening).
• Timeline to effect: Acute anxiolytic effects may be noticeable within 1–2 weeks. Full effects on cortisol, cognition, and physical performance typically require 4–8 weeks of consistent use. Most clinical trials run 8–12 weeks.

Side Effects and Safety

Ashwagandha is generally well tolerated in clinical trials lasting up to 3 months. The most common side effects are mild and gastrointestinal:

• GI discomfort: Nausea, stomach upset, and diarrhoea, typically at higher doses or on an empty stomach. Taking ashwagandha with food usually resolves this.
• Drowsiness: Some users report mild sedation, particularly with Sensoril or higher doses. This is generally considered a feature for evening use rather than a side effect.
• Rare liver injury: There have been isolated case reports of hepatotoxicity associated with ashwagandha use. While extremely uncommon, individuals with pre-existing liver conditions should exercise caution and discuss supplementation with a physician.

Contraindications and interactions:

• Pregnancy: Ashwagandha is contraindicated in pregnancy. Some animal studies suggest it may have abortifacient properties at high doses.
• Thyroid medications: Ashwagandha may increase thyroid hormone levels (T3 and T4). Individuals with hyperthyroidism or those taking thyroid hormone replacement should consult their doctor, as dose adjustments may be needed.
• Diabetes medications: Ashwagandha can lower blood glucose. Combined with insulin or oral hypoglycaemics, this may increase the risk of hypoglycaemia.
• Immunosuppressants: Ashwagandha has immunomodulatory effects and may interfere with immunosuppressive therapy. It should be avoided by individuals taking medications for autoimmune conditions or post-transplant.
• Sedatives and CNS depressants: Given ashwagandha's GABAergic activity, combining it with benzodiazepines, barbiturates, or other sedatives may produce additive effects.

Long-term safety data beyond 3 months is limited. Cycling — 8 weeks on, 2–4 weeks off — is a common precautionary approach in the nootropics community, though there is no clinical evidence specifically mandating it.

How It Fits into a Nootropic Stack

Ashwagandha occupies a distinct niche in nootropic stacking. It is not a cognitive enhancer in the traditional sense — it is a stress modulator and HPA axis regulator. Its value in a stack comes from creating the physiological conditions under which other nootropics and the brain itself perform better.

• With modafinil: This is a particularly logical pairing. Modafinil provides potent wakefulness and focus but can produce a tense, anxious quality of alertness in some users. Ashwagandha smooths that edge by lowering cortisol and modulating GABA. It does not blunt modafinil's eugeroic effect — it simply makes the focus feel less pressured. Taking ashwagandha daily as a baseline and modafinil as needed on demanding days is a common approach.
• With L-theanine: Both compounds are anxiolytic but through different mechanisms. L-theanine promotes alpha waves and has an acute onset (30–60 minutes); ashwagandha modulates the HPA axis and builds over weeks. They are complementary rather than redundant. L-theanine for situational calm, ashwagandha for baseline stress resilience.
• As a standalone daily adaptogen: For individuals who are not interested in stimulant nootropics but want better stress management, improved sleep, and the long-term cognitive and physical benefits that come from lower chronic cortisol, ashwagandha alone is a reasonable choice. It is one of the few supplements with converging evidence across stress, cognition, sleep, and physical performance.

Key Takeaways

• Ashwagandha is an adaptogen with over 3,000 years of traditional use and a growing body of RCT evidence, particularly for stress and cortisol reduction
• The stress evidence is strong: multiple trials consistently show 25–45% reductions in perceived stress and significant cortisol decreases at 240–600mg/day
• Cognitive benefits are emerging — improvements in memory, attention, and processing speed have been demonstrated in both impaired and healthy populations, though sample sizes remain small
• Sleep quality improvements are well-supported, likely mediated through cortisol reduction and GABAergic activity
• Physical performance data is surprisingly robust, with improvements in strength, VO2 max, and testosterone in resistance-trained individuals
• KSM-66 has the broadest evidence base; Sensoril may be preferred for targeted anxiety and cortisol reduction
• Allow 4–8 weeks for full effects; ashwagandha is a chronic-use compound, not an acute performance enhancer
• Generally safe for up to 3 months, but contraindicated in pregnancy and may interact with thyroid, diabetes, immunosuppressant, and sedative medications